Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Clinical Oncology

• Publication date

  1997-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1997.15.6.2403PMID 9196156
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

  2004cited by this paper
• Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

  2004cited by this paper
• Pain and depression in patients with newly diagnosed pancreas cancer.

  1995cited by this paper
• Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.

  1994cited by this paper
• Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.

  1993cited by this paper
• A phase II trial of 5‐fluorouracil, leucovorin, and recombinant alpha‐2b‐interferon in advanced adenocarcinoma of the pancreas

  1992cited by this paper
• Phase II evaluation of fluorouracil and recombinant α‐2a‐interferon in previously untreated patients with pancreatic adenocarcinoma

  1992cited by this paper
• Pancreatic carcinoma.

  1992cited by this paper
• Symptoms of pancreatic cancer.

  1991cited by this paper
• Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer.

  1991cited by this paper
• Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

  1991cited by this paper
• Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial.

  1991cited by this paper
• Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.

  1991cited by this paper
• A phase II multi‐institutional trial of low‐dose N‐(phosphonacetyl)‐L‐aspartate and high‐dose 5‐fluorouracil as a short‐term infusion in the treatment of adenocarcinoma of the pancreas. A southwest oncology group study

  1991cited by this paper
• A phase III comparison trial of streptozotocin, mitomycin, and 5‐fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

  1991cited by this paper
• A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5‐fluorouracil, doxorubicin, and cisplatin

  1990cited by this paper
• Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.

  1990cited by this paper
• Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

  1990cited by this paper
• Management of pain in pancreatic cancer.

  1989cited by this paper
• Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine.

  1989cited by this paper
• A phase III trial of 5‐fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A mayo clinic/north central cancer treatment group study

  1989cited by this paper
• Pain management of pancreatic carcinoma: a review

  1989cited by this paper
• Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.

  1988cited by this paper
• Continuous 5‐Fluorouracil (5FU) Infusion in Carcinoma of the Pancreas: A Phase II Study

  1988cited by this paper
• The memorial pain assessment card. A valid instrument for the evaluation of cancer pain

  1987cited by this paper
• The prevalence of pain in four cancers

  1987cited by this paper
• A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.

  1985cited by this paper
• Randomized study of 5‐FU and ccnu in pancreatic cancer: Report of the veterans administration surgical adjuvant cancer chemotherapy study group

  1981cited by this paper
• 5‐Fluorouracil, adriamycin, and mitomycin‐C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas

  1980cited by this paper
• Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

  1980cited by this paper
• Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.

  1980cited by this paper
• Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.

  1980cited by this paper
• Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones".

  1979cited by this paper
• Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM).

  1979cited by this paper
• Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer

  1978cited by this paper
• Mitomycin C: a review.

  1976cited by this paper
• The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma.

  1975cited by this paper
• A controlled study of combined 1,3‐bis‐(2‐chloroethyl)‐1‐nitrosourea and 5‐fluorouracil therapy for advanced gastric and pancreatic cancer

  1974cited by this paper
• Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.

  1974cited by this paper
• Treatment of cancer with weekly intravenous 5‐fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG)

  1971cited by this paper
• Treatment of cancer with weekly intravenous 5‐fluorouracil

  1968cited by this paper
• [Cancer of the pancreas].

  1965cited by this paper

• Advances in pyrimidine-like heterocyclic scaffolds: Innovative synthetic method for malic enzyme inhibition in pancreatic ductal adenocarcinoma (PDAC) - A comprehensive review.

  2026cites this paper
• Current Systemic Treatment Options for Advanced Pancreatic Cancer—An Overview Article

  2026cites this paper
• Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Preclinical Pancreatic Cancer Models.

  2026cites this paper
• The gene expression alterations in chronic hypoxic PANC-1 pancreatic cancer cell line

  2026cites this paper
• NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial

  2026cites this paper
• Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma.

  2026cites this paper
• In vitro investigations of troxacitabine (TROX) and 3'-deazanepanocin (DZNep) combination for pancreatic cancer therapy.

  2026cites this paper
• Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter study.

  2026cites this paper
• Systematic Evaluation of Transfer Learning Strategies for Clinical Chemotherapy Response Prediction

  2026cites this paper
• Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis

  2026cites this paper
• DPP4 suppresses pancreatic cancer growth by enhancing ferroptosis sensitivity through stabilization of ACSL4.

  2026cites this paper
• Developments & Potential of Nanotechnology for the Detection and Treatment of Pancreatic Cancer

  2026influential citation
• AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report

  2026cites this paper
• CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2–CCL2, CCR5–CCL5, CCR4–CCL17/22, CCR6–CCL20, CCR7–CCL19/21

  2026cites this paper
• Clinical application and drug resistance mechanism of gemcitabine

  2025cites this paper
• Tumor microenvironment phenotyping guides precision therapy in unresectable pancreatic cancer

  2025cites this paper
• Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study

  2025cites this paper
• Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future

  2025cites this paper
• Therapeutic pancreatic cancer biomarkers and pharmacogenetics.

  2025cites this paper
• Indian Consensus Guidelines for the Management of Pancreatic Cancer

  2025cites this paper
• TRANSPIRE-DRP: a deep learning framework for translating patient-derived xenograft drug response to clinical patients via domain adaptation

  2025cites this paper
• Advances in the Management of Pancreatic Cancer: Current Strategies and Emerging Therapies

  2025influential citation
• The Natural Compound CalebinA Suppresses Gemcitabine Resistance and Tumor Progression by Inhibiting Angiogenesis and Invasion Through NF-κB Signaling in Pancreatic Cancer

  2025influential citation
• Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer.

  2025cites this paper
• Oligometastatic disease in pancreatic cancer: is there a role for curative-intent surgery? A narrative review

  2025cites this paper
• Cost‐Effectiveness Analysis of First‐Line Chemotherapy for Metastatic Pancreatic Cancer in Japan

  2025cites this paper
• Efficacy and Safety of Different Sequences for mFOLFIRINOX (or SOXIRI) and Gemcitabine Plus Albumin-Bound Paclitaxel in Unresectable Pancreatic Cancer

  2025cites this paper
• Nanoparticle-induced toxicity in pancreatic cancer: Insights from machine learning models

  2025cites this paper
• Adjuvant treatment after surgical resection of pancreatic cancer

  2025cites this paper
• Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 Study.

  2025cites this paper
• Advances in AI-Driven Applications of Metal-Organic Frameworks for the Diagnosis and Treatment of Pancreatic Cancer

  2025cites this paper
• Oncolytic viral therapy as a novel potential solution for treatment of pancreatic cancer

  2025influential citation
• A Polymer–Lipid Nanosystem Comprising siRNA and Gemcitabine for Pancreatic Cancer Treatment

  2025cites this paper
• Identification of prognostic and therapeutic biomarkers associated with macrophage and lipid metabolism in pancreatic cancer

  2025cites this paper
• Prognostic Significance of ABO Blood Type in Patients with Advanced Pancreatic Cancer Treated with Nab-Paclitaxel Plus Gemcitabine.

  2025cites this paper
• Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer

  2025cites this paper
• Contributions of Low-frequency-mutated Genes in Pancreatic Tumorigenesis and Their Implications in Precision Cancer Therapy

  2025cites this paper
• Survival Outcomes in Nonmetastatic pT4 Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis Comparing Neoadjuvant Therapy and Upfront Surgery with Propensity Score Matching

  2025cites this paper
• Solid lipid nanoparticles in pancreatic cancer treatment

  2025influential citation
• Unconventional Treatments for Pancreatic Cancer: A Systematic Review

  2025cites this paper
• Twenty-five years of WWOX insight in cancer: a treasure trove of knowledge

  2025cites this paper
• Real-World Advances in Metastatic Pancreatic Cancer Treatment in the Pre-Molecular Era: A Retrospective Single-Center Analysis 2010–2018

  2025cites this paper
• Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.

  2025cites this paper
• ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel

  2025cites this paper
• Factores pronósticos y supervivencia en pacientes operados de adenocarcinoma ductal de páncreas: análisis retrospectivo multicéntrico

  2025cites this paper
• Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting

  2025cites this paper
• SMUG1 promoted the progression of pancreatic cancer via AKT signaling pathway through binding with FOXQ1

  2025cites this paper
• GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer

  2025cites this paper
• Real-World Evidence of the Efficacy and Safety of Second-Line Therapy After Gemcitabine and Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer

  2025cites this paper
• Discovery of a novel STAT3 inhibitor: A potential application for pancreatic cancer treatment.

  2025cites this paper
• Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer

  2025cites this paper
• Adjuvant Radiation for Resected Pancreatic Cancer: Historical Review and Current State.

  2025cites this paper
• Emerging Systemic Therapy Considerations for Pancreatic Cancer.

  2025cites this paper
• REG3A promotes gemcitabine resistance in pancreatic cancer via the GPR54/ARRB2/ERK1/2 ligand-directed signaling pathway.

  2025cites this paper
• TG6002 oncolytic vaccinia virus and chemotherapy synergy: a promising strategy for pancreatic ductal adenocarcinoma

  2025cites this paper
• IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis

  2025cites this paper
• Proteomic Characterization of Primary Human Pancreatic Cancer Cell Lines Following Long-Term Exposure to Gemcitabine

  2025cites this paper
• m6A Modification-Mediated LINC01547 Promotes Pancreatic Cancer Growth and Gemcitabine Resistance Through miR-34a-5p/MYH9 Axis.

  2025cites this paper
• Impact of SERPINA3 on the Prognostic Role of KRAS G12R‐Mutated Pancreatic Ductal Adenocarcinoma Patients Receiving Gemcitabine‐Based Treatment: A Cross‐Sectional Study

  2025cites this paper
• Efficacy and safety of EGFR monoclonal antibody combined with gemcitabine-based chemotherapy in first-line treatment of locally advanced unresectable or metastatic pancreatic cancer

  2025influential citation
• Biomechanical 3D tumor models on a micro-milled high-throughput force sensor array

  2025cites this paper
• Unveiling and stratifying cell cycle-dependent drug efficacy using a single-cell PLOM-CON approach with correlation anomaly and presage protein signals

  2025cites this paper
• Combined Omipalisib and MAPK Inhibition Suppress PDAC Growth

  2025cites this paper
• State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review

  2025influential citation
• A novel gemcitabine analog as a potential anticancer agent: synthesis and in-vitro evaluation against pancreatic cancer.

  2025cites this paper
• Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs.

  2025cites this paper
• Treatment Innovations in Pancreatic Cancer: Putting Patient Priorities First.

  2025cites this paper
• RNA binding protein Pumilio2 promotes chemoresistance of pancreatic cancer via focal adhesion pathway and interacting with transcription factor EGR1

  2025cites this paper
• Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma

  2025influential citation
• NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design

  2025cites this paper
• Genistein as a Chemo-modulatory Agent: Exploring its Potential in Chemosensitization and Combinatorial Therapeutic Strategies for Cancer Treatment.

  2025cites this paper
• Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)

  2025cites this paper
• Outcomes of Liposomal Irinotecan With 5‐FU and Leucovorin in Patients With Metastatic Pancreatic Cancer and Borderline Performance Status

  2025cites this paper
• Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter retrospective study

  2025cites this paper
• Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database

  2025cites this paper
• Deletion of ENO1 sensitizes pancreatic cancer cells to gemcitabine via MYC/RRM1-mediated glycolysis

  2025cites this paper
• RRM1 O-GlcNAcylation inhibition suppresses pancreatic cancer via TK1-mediated replication stress

  2025cites this paper
• Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort.

  2025cites this paper
• Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia

  2025cites this paper
• Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma

  2025cites this paper
• SLFN11 Deficiency-Induced Gemcitabine Resistance Is Overcome by Agents Targeting the DNA Damage Response in Pancreatic Cancer Cells

  2025cites this paper
• A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer

  2025cites this paper
• Survival and Chemotherapy in the Last 30 Days as a Quality Indicator for Pancreatic Cancer

  2025cites this paper
• Identification of Common miRNAs Differentially Expressed in Periodontitis and Pancreatic Cancer

  2025cites this paper
• Inhibition of autophagy by Atg7 knockdown enhances chemosensitivity in gemcitabine/paclitaxel-resistant pancreatic cancer MIAPaCa2 cells.

  2025cites this paper
• Real-world predictive models for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer

  2025cites this paper
• Optimizing In Vitro Lung Cancer Therapy with Folate-Conjugated Polydopamine-Coated Liposomes Loaded with Gemcitabine.

  2025cites this paper
• Paracrine regulation of pancreatic cancer cell response to chemotherapy by GLI2–collagen I signaling

  2025cites this paper
• Icaritin and lenvatinib treatment for unresectable localized progressive pancreatic cancer: a report of six cases

  2025cites this paper
• Exosome-mediated triple drug delivery enhances apoptosis in pancreatic cancer cells

  2025cites this paper
• USP10 promotes the progression and attenuates gemcitabine chemotherapy sensitivity via stabilizing PLK1 in PDAC

  2025cites this paper
• Current progress in targeting mitotic kinases in PDAC.

  2025cites this paper
• Current perspectives and future strategies of chemotherapy for pancreatic cancer: a narrative review

  2025cites this paper
• Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors.

  2025cites this paper
• Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses and sensitizing cells to gemcitabine.

  2025cites this paper
• CF33-hNIS-antiPDL1 enhances immunogenicity and anti-tumor efficacy in an orthotopic syngeneic pancreatic cancer mouse model.

  2025cites this paper
• Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

  2025cites this paper
• Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal adenocarcinoma.

  2025cites this paper
• Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy

  2025cites this paper
• Actualización del cáncer de páncreas

  2025cites this paper